Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population - PubMed (original) (raw)
Clinical Trial
. 2005 Feb;288(2):E462-8.
doi: 10.1152/ajpendo.00064.2004. Epub 2004 Aug 31.
Affiliations
- PMID: 15339742
- DOI: 10.1152/ajpendo.00064.2004
Free article
Clinical Trial
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population
Lidia S Szczepaniak et al. Am J Physiol Endocrinol Metab. 2005 Feb.
Free article
Abstract
Despite the increasing prevalence of nonalcoholic fatty liver disease (NAFLD), the criteria used to diagnose the disorder remain poorly defined. Localized proton magnetic resonance spectroscopy (MRS) accurately measures hepatic triglyceride content (HTGC) but has been used only in small research studies. Here, MRS was used to analyze the distribution of HTGC in 2,349 participants from the Dallas Heart Study (DHS). The reproducibility of the procedure was validated by showing that duplicate HTGC measurements were high correlated (r = 0.99, P < 0.001) and that the coefficient of variation between measurements was low (8.5%). Intake of a high-fat meal did not significantly affect the measurements, and values were similar when measurements were made from the right and left hepatic lobes. To determine the "upper limit of normal" for HTGC, the distribution of HTGC was examined in the 345 subjects from the DHS who had no identifiable risk factors for hepatic steatosis (nonobese, nondiabetic subjects with minimal alcohol consumption, normal liver function tests, and no known liver disease). The 95th percentile of HTGC in these subjects was 5.56%, which corresponds to a hepatic triglyceride level of 55.6 mg/g. With this value as a cutoff, the prevalence of hepatic steatosis in Dallas County was estimated to be 33.6%. Thus MRS provides a sensitive, quantitative, noninvasive method to measure HTGC and, when applied to a large urban US population, revealed a strikingly high prevalence of hepatic steatosis.
Similar articles
- Reproducibility of hepatic triglyceride content assessment in normals using localized magnetic resonance spectroscopy.
Kullberg J, Ortiz-Nieto F, Johansson L. Kullberg J, et al. Diabetes Obes Metab. 2009 May;11(5):516-8. doi: 10.1111/j.1463-1326.2008.00979.x. Diabetes Obes Metab. 2009. PMID: 19422403 - Reproducibility of 3.0 Tesla magnetic resonance spectroscopy for measuring hepatic fat content.
van Werven JR, Hoogduin JM, Nederveen AJ, van Vliet AA, Wajs E, Vandenberk P, Stroes ES, Stoker J. van Werven JR, et al. J Magn Reson Imaging. 2009 Aug;30(2):444-8. doi: 10.1002/jmri.21837. J Magn Reson Imaging. 2009. PMID: 19629974 - Statins and hepatic steatosis: perspectives from the Dallas Heart Study.
Browning JD. Browning JD. Hepatology. 2006 Aug;44(2):466-71. doi: 10.1002/hep.21248. Hepatology. 2006. PMID: 16871575 - Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
Choi SS, Diehl AM. Choi SS, et al. Curr Opin Lipidol. 2008 Jun;19(3):295-300. doi: 10.1097/MOL.0b013e3282ff5e55. Curr Opin Lipidol. 2008. PMID: 18460922 Review. - Epidemiology of nonalcoholic fatty liver.
Ruhl CE, Everhart JE. Ruhl CE, et al. Clin Liver Dis. 2004 Aug;8(3):501-19, vii. doi: 10.1016/j.cld.2004.04.008. Clin Liver Dis. 2004. PMID: 15331060 Review.
Cited by
- Effects of Obesity and Exercise on Hepatic and Pancreatic Lipid Content and Glucose Metabolism: PET Studies in Twins Discordant for BMI.
Lietzén MS, Mari A, Ojala R, Hentilä J, Koskensalo K, Lautamäki R, Löyttyniemi E, Parkkola R, Saunavaara V, Kirjavainen AK, Rajander J, Malm T, Lahti L, Rinne JO, Pietiläinen KH, Iozzo P, Hannukainen JC. Lietzén MS, et al. Biomolecules. 2024 Aug 27;14(9):1070. doi: 10.3390/biom14091070. Biomolecules. 2024. PMID: 39334836 Free PMC article. - Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy.
Habib S. Habib S. World J Gastrointest Pathophysiol. 2024 Aug 22;15(4):93606. doi: 10.4291/wjgp.v15.i4.93606. World J Gastrointest Pathophysiol. 2024. PMID: 39220834 Free PMC article. Review. - Underexplored Molecular Mechanisms of Toxicity.
Arowolo O, Suvorov A. Arowolo O, et al. J Xenobiot. 2024 Jul 18;14(3):939-949. doi: 10.3390/jox14030052. J Xenobiot. 2024. PMID: 39051348 Free PMC article. - Exploring factors associated with non-alcoholic fatty liver disease using longitudinal MRI.
Horn F, Ittermann T, Kromrey ML, Seppelt D, Völzke H, Kühn JP, Schön F. Horn F, et al. BMC Gastroenterol. 2024 Jul 23;24(1):229. doi: 10.1186/s12876-024-03300-0. BMC Gastroenterol. 2024. PMID: 39044153 Free PMC article. - Linking fatty liver diseases to hepatocellular carcinoma by hepatic stellate cells.
Chen L, Ye X, Yang L, Zhao J, You J, Feng Y. Chen L, et al. J Natl Cancer Cent. 2024 Jan 18;4(1):25-35. doi: 10.1016/j.jncc.2024.01.002. eCollection 2024 Mar. J Natl Cancer Cent. 2024. PMID: 39036388 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- K25 HL 68736/HL/NHLBI NIH HHS/United States
- M01 RR 00633/RR/NCRR NIH HHS/United States
- P01 HL 2098/HL/NHLBI NIH HHS/United States
- R01 DK 57558/DK/NIDDK NIH HHS/United States
- T32 DK 07745/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources